Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Itrade

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Jul 25, 2021 8:31pm

221 Views

Post# 33602575

Itrade

Itrade has my original qty b4 split...but they have market price at 0.02 and this is what is calculated as my price per share balance in my account.... pps close was 0.0225 b4 split ....my account is short 575 as it stands ...hopefully will be adjusted correctly....with ticker code change my account opened back up 30 dollars short. because they upped 3 digit on my pps... I had a snapshot of my account b4 change... they are suppose to be investigating it and still no response ...the first rep tried to tell me no it wasn't changed . .when I said I had a snapshot ...they tried to say maybe surcharge for doing change lol ... anyways heads up on Itrade to make sure calculations is based on 0.0225 not 0.02 on pps b4 split

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand